Amgen (AMGN) has been receiving increased attention in the market with its four-quarter averages seeing
profit margins surge to 19%. Wall Street firms including BMO Capital, Goldman Sachs and Guggenheim Capital have either maintained or raised their price targets for AMGN. Additionally, Amgen's stock has soared following quarterly earnings release that surpassed expectations. This strong financial performance comes as the company's new drugs, such as the cholesterol treatment
MariTide, deliver promising data. Despite market fluctuations and concerns about potential stagnation, the biotechnology firm's outlook remains broadly positive with revenue growth and robust pipeline updates suggesting a strong future earnings narrative. However, multiple investment firms have trimmed their stock holdings in Amgen, reflecting some level of uncertainty. With some big wins recently, including full
FDA approval for IMDELLTRA in small cell lung cancer and the successful launch of
AmgenNow, the firm is also investing significantly in innovation, including a $650M expansion of their U.S. manufacturing facilities. Over the last five years, investors in Amgen have enjoyed decent returns of 76%, and the stock continues to be a trending topic amongst investors.
Amgen AMGN News Analytics from Tue, 15 Jul 2025 07:00:00 GMT to Sat, 06 Dec 2025 19:00:58 GMT -
Rumor -7
